Issue Date: February 28, 2011
Forest Labs To Buy Clinical Data Inc.
Looking to acquire new products that will offset declining revenues from drugs facing patent expirations, Forest Laboratories will pay up to $1.2 billion to own the specialty pharmaceutical firm Clinical Data, based in Newton, Mass. In January, FDA approved Clinical Data’s new antidepressant Viibryd (vilazodone), which is a selective serotonin reuptake inhibitor and a 5-HT1A receptor partial agonist. Forest plans to launch Viibryd in the second half of 2011. According to the company, the drug is patent protected at least until March 2020.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society